HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[The value of portal vein chemotherapy after radical resection in delaying intrahepatic recurrence of stage II primary hepatocellular carcinoma].

AbstractBACKGROUND & OBJECTIVE:
Hepatectomy is now considered as the most effective treatment for hepatocellular carcinoma (HCC). High recurrence rate after operation is the main factor to impact the curative effect. The options of treatment for preventing postoperative recurrence of HCC are controversial. This study was to explore the value of postoperative portal vein chemotherapy (PVC) in delaying recurrence of stage II HCC, and to evaluate the risk factors of recurrence.
METHODS:
A total of 51 patients with pathologically proved stage II HCC, who underwent radical resection from February 2003 to February 2007 in Xinjiang Tumor Hospital, were randomly divided into two groups: 24 underwent radical resection alone (control group), and 27 underwent prophylactic PVC after operation (study group). Disease-free survival statuses and median survival time of the patients were analyzed by Kaplan-Meier method; clinical and pathologic factors such as number of nodules, portal vein tumor thrombus, cirrhosis, differentiation level, prophylactic PVC were analyzed by Cox model.
RESULTS:
The 6-month, 1-, 2-and 3-year disease-free survival rates were 44.4%, 38.9%, 19.4% and 14.3% in control group, and 75.4%, 61.3%, 49.0% and 31.5% in study group. The median survival time was significantly higher in study group than in control group (15.5 months vs. 5.6 months, P<0.05). Cox multivariate analysis showed that number of nodules, portal vein tumor thrombus, and PVC were impact factors of the recurrence for stage II HCC ( P<0.05). Furthermore, PVC significantly increased the 1-year disease-free survival rate of stage II HCC patients after operation.
CONCLUSION:
Prophylactic PVC can delay early recurrence of stage II HCC with multiple lesions or portal vein tumor thrombus.
AuthorsGuo-Qing Zhang, Lei Ge, Wei Ding, Hai-Jun Li
JournalAi zheng = Aizheng = Chinese journal of cancer (Ai Zheng) Vol. 27 Issue 12 Pg. 1297-301 (Dec 2008) China
PMID19079997 (Publication Type: English Abstract, Journal Article, Randomized Controlled Trial)
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma, Hepatocellular (drug therapy, pathology, surgery)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Hepatectomy
  • Humans
  • Infusions, Intravenous
  • Liver Neoplasms (drug therapy, pathology, surgery)
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (prevention & control)
  • Neoplasm Staging
  • Neoplastic Cells, Circulating
  • Portal Vein
  • Proportional Hazards Models
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: